Share to: share facebook share twitter share wa share telegram print page

 

Kenneth L. Davis

Kenneth L. Davis, MD
NationalityAmerican
EducationMount Sinai School of Medicine, Stanford University School of Medicine, Stanford University Hospital
Occupation(s)Executive vice chairperson of the board of trustees at the Mount Sinai Health System
Known forPsychiatry
Medical career
FieldPsychiatry, Alzheimer's disease, schizophrenia
InstitutionsMount Sinai Health System
Notable worksAlzheimer's Disease Assessment Scale
AwardsGeorge H. W. Bush Lifetime of Leadership Award
WebsiteKenneth L. Davis, MD

Kenneth L. Davis is the executive vice chairperson of the board of trustees at the Mount Sinai Health System in New York City,[1][2] and an American author and medical researcher who developed the Alzheimer's Disease Assessment Scale, the most widely used tool to test the efficacy of treatments for Alzheimer's disease designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic to persons with Alzheimer's disease.[3][4] His research led to four of the first five FDA-approved drugs for Alzheimer's.[5]

Biography

Education

Davis graduated magna cum laude from Yale College in 1969 and was the valedictorian of Mount Sinai School of Medicine's second graduating class in 1973 with his M.D., where he received the Harold Elster Memorial Award for highest academic achievement.[6] Supplementary graduate medical education was later completed at Stanford University.

Career

In 1979, Davis was made chief of psychiatry at Bronx Veteran's Affairs Medical Center, where he became the first director of its Schizophrenia Biological Research Center. From 1987 until 2003, he was chairman of psychiatry at Mount Sinai School of Medicine.

In 2003, Davis was appointed dean of Mount Sinai School of Medicine and held that position until 2007, when he was succeeded by Dennis S. Charney, M.D. Davis was also appointed as the president and CEO of Mount Sinai Medical Center in 2003 – a position he held until 2024. In 2015, Davis had gross compensation from the Icahn School of Medicine at Mount Sinai of $4,147,755.[relevant?] He is the director of the Mount Sinai Silvio Conte Neuroscience Center, trustee of the New York Academy of Medicine, trustee of the Aspen Institute,[7][8] and chair of the New York Academy of Medicine Deans Council. In addition, he has served as chairman of the board of governors for the Greater New York Hospital Association.

In September 2013, when Mount Sinai Medical Center merged with Continuum Health Partners, Davis became the president and CEO of the Mount Sinai Health System. In 2017, his annual salary was $12 million.[9][relevant?]

Davis has weighed in on the intersection of health and public policy, arguing that the National Institutes of Health should receive more funds to fight disease and calling drug prices 'outrageous' and a fair trade issue.[10][11]

Awards and recognition

Research

Alzheimer's research

Davis participated in breakthrough proof-of-concept studies and clinical trials of cholinesterase inhibitors. These trials (the first multicenter ones for cholinesterase inhibitors) established efficacy and ultimately led to the first four of the five FDA-approved compounds for treating the symptoms of Alzheimer's: tacrine, rivastigmine, galantamine, donepezil and memantine[15][5]

In 1978, Davis, together with Richard Mohs, conducted the first well-controlled study of a drug that was shown able to improve the storage and retrieval functions of long-term memory in humans.[16]

In 1987, Davis participated in the first study providing strong evidence that Alzheimer's risk is inherited.[17]

His Alzheimer Disease Assessment Scale (ADAS) is one of two primary cognitive measures used for all Food and Drug Administration (FDA) Altzheimer's-related clinical drug trials in the US.[18]

While at Mount Sinai Hospital, Davis and his associates have been at the forefront in the delineation of the role of amyloid in Alzheimer's disease,[16] and were among the first to report the cloning and chromosomal location of the amyloid precursor protein, regarded as one of the most important discoveries in Alzheimer's research in the previous 15 years.[19]

Schizophrenia research

Davis's work on schizophrenia has shown that oligodendroglia cells and myelin play roles in the disease's pathophysiology[20] and that dopamine – long thought to be merely hyperactive in a schizophrenic brain – is actually hypoactive in different regions.[21]

His paper, "Dopamine in schizophrenia—a review and reconceptualization" (American Journal of Psychiatry, 148-11: 1474–86, November 1991) is the third most-cited paper on schizophrenia research in its decade.[22]

While studies have shown that individuals born in winter months are disproportionately likely to develop schizophrenia, Davis participated in a 2006 study that demonstrated that this disproportionality also exists in tropical regions, ruling out cold weather as the cause.[23]

Publications

Editor and editorial roles

Books

  • Alzheimer's Disease: Questions and Answers by Kenneth Davis and Kenneth L Davis and Paul S. Aisen and Deborah B. Marin, Softcover, Merit Pub Intl, ISBN 1-873413-36-X (1-873413-36-X)
  • Brain Acetylcholine and Neuropsychiatric Disease by Philip A. Berger and Kenneth L Davis, Hardcover, Plenum Press, ISBN 0-306-40157-6 (0-306-40157-6)
  • Neuropsychopharmacology: The Fifth Generation of Progress by American College of Neuropsychopharmacology and Joseph T. Coyle and Charles Nemeroff and Dennis Charney and Kenneth L Davis, Hardcover, Lippincott Williams & Wilkins, ISBN 0-7817-2837-1 (0-7817-2837-1)
  • Alzheimer's Disease: A Report of Progress in Research  S Corkin, J Growdon, E Usdin, KL Davis, RJ Wurtman (eds.). Raven Press, New York, NY, 1982. ISBN 0890046859
  • Handbook for Clinical Memory Assessment of Older Adults LW Poon (editor)  KL Davis, et al (Associate Editors) American Psychological Association, Hyattsville, MD, 1986.[24] ISBN 978-0912704425
  • Advisory Panel on Alzheimer’s Disease. Report of the Advisory Panel on Alzheimer’s Disease  DHHS Pub. No. (ADM)89-1644.  Washington, DC: Supt. Of Docs., U.S. Govt. Print. Off., 1989.
  • Advisory Panel on Alzheimer’s Disease  Second Report of the Advisory Panel on Alzheimer’s Disease.  DHHS Pub. No. (ADM)91-1791.  Washington, DC: Supt. Of Docs., U.S. Govt. Print Off., 1991.
  • Foundations of Psychiatry  KL Davis, H Klar and JT Coyle (eds.).  W.B. Saunders, Philadelphia, PA, 1991. ISBN 0721613411

Articles

According to ResearchGate, Davis' peer-reviewed articles have been cited 28,265 times. He is credited with more than 575 articles.[5] Select list:

  • Ripke, Stephan, et al. "Biological insights from 108 schizophrenia-associated genetic loci." Nature 511.7510 (2014): 421.[25] Cited: 5762[26]
  • Rosen, Wilma G., Richard C. Mohs, and Kenneth L. Davis. "A new rating scale for Alzheimer's disease." The American journal of psychiatry (1984).[27] Cited: 4701[26]
  • Davis, Kenneth L., et al. "Dopamine in schizophrenia: a review and reconceptualization." The American journal of psychiatry (1991).[28] Cited: 2807[26]
  • Näslund, Jan, et al. "Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline." Jama 283.12 (2000): 1571-1577.[29] Cited: 1591[26]
  • Coccaro, Emil F., et al. "Serotonergic studies in patients with affective and personality disorders: correlates with suicidal and impulsive aggressive behavior." Archives of general psychiatry 46.7 (1989): 587-599.[30] Cited: 1520[26]
  • Hakak, Yaron, et al. "Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia." Proceedings of the National Academy of Sciences 98.8 (2001): 4746-4751.[31] Cited: 1433[26]
  • Siever, Larry J., and Kenneth L. Davis. "A psychobiological perspective on the personality disorders." The American journal of psychiatry (1991).[32] Cited: 1166[26]

References

  1. ^ "Mount Sinai Boards of Trustees Announce Updated Leadership Structure | Mount Sinai - New York". Mount Sinai Health System. Retrieved 2021-11-09.
  2. ^ Neber, Jaqueline (November 21, 2023). "Mount Sinai Health System names Dr. Brendan Carr as next CEO". Craine's New York Business. Retrieved January 14, 2023.
  3. ^ A new rating scale for Alzheimer's disease, American Journal of Psychiatry
  4. ^ "Mt Sinai Hospital -- IRS Form 990 2017". Pro Publica Non Profit Explorer. 9 May 2013. Retrieved July 1, 2019.
  5. ^ a b c "How Dr. Kenneth Davis Turned the Mount Sinai Health System Around". 1A. Retrieved 2022-04-27.
  6. ^ New York Times
  7. ^ "Board of Trustees – The Aspen Institute". The Aspen Institute. Retrieved 2017-05-16.
  8. ^ Institute, The Aspen. "Six Leaders Elected to Aspen Institute Board of Trustees". www.prnewswire.com. Retrieved 2017-05-16.
  9. ^ "Mt Sinai Hospital IRS Form 990, Return of Organization Exempt From Income Tax (2017)". Pro Publica Nonprofit Explorer. July 1, 2019. Retrieved July 1, 2019.
  10. ^ Bachai, Sabrina (2017-12-05). "Congress should massively ramp up funding for the NIH". TheHill. Retrieved 2018-06-06.
  11. ^ Fox, Michelle (2018-05-17). "'Outrageous' drug prices are a fair trade issue: Mt. Sinai CEO". CNBC. Retrieved 2018-06-06.
  12. ^ "Archived copy". Archived from the original on 2015-03-09. Retrieved 2015-04-06.{{cite web}}: CS1 maint: archived copy as title (link)
  13. ^ "Yale Bulldogs: Yale Athletic Department Hosts Blue Leadership Ball". Retrieved December 31, 2009.
  14. ^ "100 Most Influential People in Healthcare - Dr. Kenneth Davis". Modern Healthcare. 2021-12-09. Retrieved 2022-04-27.
  15. ^ U.S. Food and Drug Administration
  16. ^ a b Science Magazine
  17. ^ Strong New Evidence Found of Inherited Alzheimer Risk, New York Times
  18. ^ "Alzheimer Disease Assessment Scale - an overview | ScienceDirect Topics". www.sciencedirect.com. Retrieved 2022-04-27.
  19. ^ The Journal of the American Medical Association
  20. ^ Myelin and oligodendrocyte abnormalities in schizophrenia, Cambridge Journals
  21. ^ Schizophrenia, Bipolar May Share Cause, WebMD.com
  22. ^ Science Watch
  23. ^ Seasonality effects on schizophrenic births in multiplex families in a tropical island
  24. ^ "APA PsycNet". psycnet.apa.org. Retrieved 2022-04-27.
  25. ^ Ripke, Stephan; Neale, Benjamin M; Corvin, Aiden; Walters, James TR; Farh, Kai-How; Holmans, Peter A; Lee, Phil; Bulik-Sullivan, Brendan; Collier, David A; Huang, Hailiang; Pers, Tune H (2014-07-24). "Biological Insights From 108 Schizophrenia-Associated Genetic Loci". Nature. 511 (7510): 421–427. Bibcode:2014Natur.511..421S. doi:10.1038/nature13595. ISSN 0028-0836. PMC 4112379. PMID 25056061.
  26. ^ a b c d e f g "Google Scholar". scholar.google.com. Retrieved 2022-04-27.
  27. ^ "APA PsycNet". psycnet.apa.org. Retrieved 2022-04-27.
  28. ^ "APA PsycNet". psycnet.apa.org. Retrieved 2022-04-27.
  29. ^ Näslund, Jan; Haroutunian, Vahram; Mohs, Richard; Davis, Kenneth L.; Davies, Peter; Greengard, Paul; Buxbaum, Joseph D. (2000-03-22). "Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline". JAMA. 283 (12): 1571–1577. doi:10.1001/jama.283.12.1571. ISSN 0098-7484. PMID 10735393.
  30. ^ Coccaro, Emil F.; Siever, Larry J.; Klar, Howard M.; Maurer, Gail; Cochrane, Karen; Cooper, Thomas B.; Mohs, Richard C.; Davis, Kenneth L. (1989-07-01). "Serotonergic Studies in Patients With Affective and Personality Disorders: Correlates With Suicidal and Impulsive Aggressive Behavior". Archives of General Psychiatry. 46 (7): 587–599. doi:10.1001/archpsyc.1989.01810070013002. ISSN 0003-990X. PMID 2735812.
  31. ^ Hakak, Yaron; Walker, John R.; Li, Cheng; Wong, Wing Hung; Davis, Kenneth L.; Buxbaum, Joseph D.; Haroutunian, Vahram; Fienberg, Allen A. (2001-04-10). "Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia". Proceedings of the National Academy of Sciences. 98 (8): 4746–4751. Bibcode:2001PNAS...98.4746H. doi:10.1073/pnas.081071198. ISSN 0027-8424. PMC 31905. PMID 11296301.
  32. ^ "APA PsycNet". psycnet.apa.org. Retrieved 2022-04-27.
Kembali kehalaman sebelumnya